Chromosome Band 11q23 Deletion Predicts Poor Prognosis in Bone Marrow Metastatic Neuroblastoma Patients Without MYCN Amplification

Overview

Journal Cancer Commun (Lond)

Publisher Wiley

Specialty Oncology

Date 2019 Nov 6

PMID 31685009

Citations 6

Authors

Zhi-Xia Yue

Tian-Yu Xing

Chao Gao

Shu-Guang Liu

Wen Zhao

Qian Zhao

Xi-Si Wang

Mei Jin

Xiao-Li Ma

Affiliations

Soon will be listed here.

Abstract

Background: Interphase fluorescence in situ hybridization (FISH) of bone marrow cells has been confirmed to be a direct and valid method to assess the v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) amplification in patients with bone marrow metastatic neuroblastoma. MYCN amplification alone, however, is insufficient for pretreatment risk stratification. Chromosome band 11q23 deletion has recently been included in the risk stratification of neuroblastoma. In the present study, we aimed to evaluate the biological characteristics and prognostic impact of 11q23 deletion and MYCN amplification in patients with bone marrow metastatic neuroblastoma.

Methods: We analyzed the MYCN and 11q23 statuses of 101 patients with bone marrow metastatic neuroblastoma using interphase FISH of bone marrow cells. We specifically compared the biological characteristics and prognostic impact of both aberrations.

Results: MYCN amplification and 11q23 deletion were seen in 12 (11.9%) and 40 (39.6%) patients. The two markers were mutually exclusive. MYCN amplification occurred mainly in patients with high lactate dehydrogenase (LDH) and high neuron-specific enolase (NSE) levels (both P < 0.001), and MYCN-amplified patients had more events (tumor relapse, progression, or death) than MYCN-normal patients (P = 0.004). 11q23 deletion was associated only with age (P = 0.001). Patients with MYCN amplification had poorer outcomes than those with normal MYCN (3-year event-free survival [EFS] rate: 8.3 ± 8.0% vs. 43.8 ± 8.5%, P < 0.001; 3-year overall survival [OS] rate: 10.4 ± 9.7% vs. 63.5% ± 5.7%, P < 0.001). 11q23 deletion reflected a poor prognosis only for patients with normal MYCN (3-year EFS rate: 34.3 ± 9.5% vs. 53.4 ± 10.3%, P = 0.037; 3-year OS rate: 42.9 ± 10.4% vs. 75.9 ± 6.1%, P = 0.048). Those with both MYCN amplification and 11q23 deletion had the worst outcome (P < 0.001).

Conclusions: Chromosome band 11q23 deletion predicts poor prognosis only in bone marrow metastatic neuroblastoma patients without MYCN amplification. Combined assessment of the two markers was much superior to single-marker assessment in recognizing the patients at a high risk of disease progression.

Citing Articles

Event-free survival in neuroblastoma with MYCN amplification and deletion of 1p or 11q may be associated with altered immune status.

Wei Z, Gong B, Li X, Chen C, Zhao Q BMC Cancer. 2024; 24(1):1279.

PMID: 39407175 PMC: 11481459. DOI: 10.1186/s12885-024-13044-5.

Differentiation of early relapse and late relapse in intermediate- and high-risk neuroblastoma with an F-FDG PET/CT-based radiomics nomogram.

Feng L, Yao X, Lu X, Wang C, Wang W, Yang J Abdom Radiol (NY). 2024; 49(3):888-899.

PMID: 38315193 DOI: 10.1007/s00261-023-04181-9.

BPTF in bone marrow provides a potential progression biomarker regulated by TFAP4 through the PI3K/AKT pathway in neuroblastoma.

Jiang C, Yang Y, He S, Yue Z, Xing T, Chu P Biol Proced Online. 2023; 25(1):11.

PMID: 37170211 PMC: 10176855. DOI: 10.1186/s12575-023-00200-7.

MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma.

Yue Z, Xing T, Zhao W, Zhao Q, Wang X, Su Y Cancer Med. 2022; 11(8):1837-1849.

PMID: 35137546 PMC: 9041068. DOI: 10.1002/cam4.4583.

gene polymorphisms and neuroblastoma susceptibility in Chinese children.

Li Y, Lu T, Wang J, Zhuo Z, Miao L, Yang Z Aging (Albany NY). 2021; 13(23):25426-25439.

PMID: 34897032 PMC: 8714171. DOI: 10.18632/aging.203760.

References

Domingo-Fernandez R, Watters K, Piskareva O, Stallings R, Bray I . The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis. Pediatr Surg Int. 2013; 29(2):101-19. PMC: 3557462. DOI: 10.1007/s00383-012-3239-7. View

Stigliani S, Coco S, Moretti S, Oberthuer A, Fischer M, Theissen J . High genomic instability predicts survival in metastatic high-risk neuroblastoma. Neoplasia. 2012; 14(9):823-32. PMC: 3459278. DOI: 10.1593/neo.121114. View

Tolbert V, Matthay K . Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell Tissue Res. 2018; 372(2):195-209. PMC: 5918153. DOI: 10.1007/s00441-018-2821-2. View

Coco S, Theissen J, Scaruffi P, Stigliani S, Moretti S, Oberthuer A . Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma. Int J Cancer. 2012; 131(7):1591-600. DOI: 10.1002/ijc.27432. View

Duan C, Wang H, Chen Y, Chu P, Xing T, Gao C . Whole exome sequencing reveals novel somatic alterations in neuroblastoma patients with chemotherapy. Cancer Cell Int. 2018; 18:21. PMC: 5816515. DOI: 10.1186/s12935-018-0521-3. View

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

Spitz R, Hero B, Simon T, Berthold F . Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res. 2006; 12(11 Pt 1):3368-73. DOI: 10.1158/1078-0432.CCR-05-2495. View

Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D . Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009; 27(7):1026-33. DOI: 10.1200/JCO.2008.16.0630. View

Schleiermacher G, Janoueix-Lerosey I, Delattre O . Recent insights into the biology of neuroblastoma. Int J Cancer. 2014; 135(10):2249-61. DOI: 10.1002/ijc.29077. View

10.

Irwin M, Park J . Neuroblastoma: paradigm for precision medicine. Pediatr Clin North Am. 2014; 62(1):225-56. DOI: 10.1016/j.pcl.2014.09.015. View

11.

Villamon E, Berbegall A, Piqueras M, Tadeo I, Castel V, Djos A . Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion. PLoS One. 2013; 8(1):e53740. PMC: 3544899. DOI: 10.1371/journal.pone.0053740. View

12.

Mlakar V, Jurkovic Mlakar S, Lopez G, Maris J, Ansari M, Gumy-Pause F . 11q deletion in neuroblastoma: a review of biological and clinical implications. Mol Cancer. 2017; 16(1):114. PMC: 5492892. DOI: 10.1186/s12943-017-0686-8. View

13.

Stevens-Kroef M, Simons A, Rack K, Hastings R . Cytogenetic Nomenclature and Reporting. Methods Mol Biol. 2016; 1541:303-309. DOI: 10.1007/978-1-4939-6703-2_24. View

14.

Maris J, Guo C, White P, Hogarty M, Thompson P, Stram D . Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. Med Pediatr Oncol. 2001; 36(1):24-7. DOI: 10.1002/1096-911X(20010101)36:1<24::AID-MPO1007>3.0.CO;2-7. View

15.

Santo E, Ebus M, Koster J, Schulte J, Lakeman A, van Sluis P . Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. Oncogene. 2011; 31(12):1571-81. DOI: 10.1038/onc.2011.344. View

16.

Theissen J, Boensch M, Spitz R, Betts D, Stegmaier S, Christiansen H . Heterogeneity of the MYCN oncogene in neuroblastoma. Clin Cancer Res. 2009; 15(6):2085-90. DOI: 10.1158/1078-0432.CCR-08-1648. View

17.

Bassing C, Suh H, Ferguson D, Chua K, Manis J, Eckersdorff M . Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell. 2003; 114(3):359-70. DOI: 10.1016/s0092-8674(03)00566-x. View

18.

Morandi F, Corrias M, Pistoia V . Evaluation of bone marrow as a metastatic site of human neuroblastoma. Ann N Y Acad Sci. 2014; 1335:23-31. DOI: 10.1111/nyas.12554. View

19.

Caren H, Kryh H, Nethander M, Sjoberg R, Trager C, Nilsson S . High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A. 2010; 107(9):4323-8. PMC: 2840092. DOI: 10.1073/pnas.0910684107. View

20.

Selmi A, de Saint-Jean M, Jallas A, Garin E, Hogarty M, Benard J . TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma. Cancer Lett. 2014; 357(1):412-418. DOI: 10.1016/j.canlet.2014.11.056. View